Growth Rate of Early-stage Hepatocellular Carcinoma in Patients with Chronic Liver Disease

Overview

Journal Clin Mol Hepatol

Specialty Gastroenterology

Date 2015 Nov 3

PMID 26523271

Citations 42

Authors

Chansik An

Youn Ah Choi

Dongil Choi

Yong Han Paik

Sang Hoon Ahn

Myeong-Jin Kim

Seung Woon Paik

Kwang-Hyub Han

Mi-Suk Park

Affiliations

Soon will be listed here.

Abstract

Background/aims: The goal of this study was to estimate the growth rate of hepatocellular carcinoma (HCC) and identify the host factors that significantly affect this rate.

Methods: Patients with early-stage HCC (n=175) who underwent two or more serial dynamic imaging studies without any anticancer treatment at two tertiary care hospitals in Korea were identified. For each patient, the tumor volume doubling time (TVDT) of HCC was calculated by comparing tumor volumes between serial imaging studies. Clinical and laboratory data were obtained from the medical records of the patients.

Results: The median TVDT was 85.7 days, with a range of 11 to 851.2 days. Multiple linear regression revealed that the initial tumor diameter (a tumor factor) and the etiology of chronic liver disease (a host factor) were significantly associated with the TVDT. The TVDT was shorter when the initial tumor diameter was smaller, and was shorter in HCC related to hepatitis B virus (HBV) infection than in HCC related to hepatitis C virus (HCV) infection (median, 76.8 days vs. 137.2 days; P=0.0234).

Conclusions: The etiology of chronic liver disease is a host factor that may significantly affect the growth rate of early-stage HCC, since HBV-associated HCC grows faster than HCV-associated HCC.

Citing Articles

Tumor Growth in Overdrive: Detailing an Aggressive Course of Hepatocellular Carcinoma.

Singh S, Delungahawatta T, Wolff M, Haas C Case Reports Hepatol. 2024; 2024:4950398.

PMID: 38974801 PMC: 11226333. DOI: 10.1155/2024/4950398.

Quantifying the natural growth rate of hepatocellular carcinoma: A real-world retrospective study in southwestern China.

Tu L, Xie H, Li Q, Lei P, Zhao P, Yang F World J Hepatol. 2024; 16(5):800-808.

PMID: 38818290 PMC: 11135263. DOI: 10.4254/wjh.v16.i5.800.

Based on Gadolinium Ethoxybenzyl DTPA-Enhanced MRI: Diagnostic Performance of the Category-Modified LR-5 Criteria in Patients At Risk for Hepatocellular Carcinoma.

Li S, Deng K, Qiu J, Wang P, Yin D, Xie Y Technol Cancer Res Treat. 2024; 23:15330338241256859.

PMID: 38780516 PMC: 11131403. DOI: 10.1177/15330338241256859.

Prevention and control strategies of general surgeons under COVID-19 pandemic.

Liu F, Wang W, Yu H, Wang Y, Wu W, Qin X Surg Pract Sci. 2024; 1:100008.

PMID: 38620248 PMC: 7335414. DOI: 10.1016/j.sipas.2020.100008.

The impact of waiting time and delayed treatment on the outcomes of patients with hepatocellular carcinoma: A systematic review and meta-analysis.

Cheo F, Lim C, Chan K, Shelat V Ann Hepatobiliary Pancreat Surg. 2023; 28(1):1-13.

PMID: 38092430 PMC: 10896687. DOI: 10.14701/ahbps.23-090.

References

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

Guiot C, Degiorgis P, Delsanto P, Gabriele P, Deisboeck T . Does tumor growth follow a "universal law"?. J Theor Biol. 2003; 225(2):147-51. DOI: 10.1016/s0022-5193(03)00221-2. View

Corrao G, Bagnardi V, Zambon A, La Vecchia C . A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med. 2004; 38(5):613-9. DOI: 10.1016/j.ypmed.2003.11.027. View

Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso J . Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2007; 47(1):97-104. DOI: 10.1002/hep.21966. View

Della Corte C, Colombo M . Surveillance for hepatocellular carcinoma. Semin Oncol. 2012; 39(4):384-98. DOI: 10.1053/j.seminoncol.2012.05.002. View

Sheu J, SUNG J, Chen D, Yang P, Lai M, Lee C . Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology. 1985; 89(2):259-66. DOI: 10.1016/0016-5085(85)90324-5. View

Kudo M . Japan's Successful Model of Nationwide Hepatocellular Carcinoma Surveillance Highlighting the Urgent Need for Global Surveillance. Liver Cancer. 2013; 1(3-4):141-3. PMC: 3760465. DOI: 10.1159/000342749. View

Sadek A, Mitchell D, Siegelman E, Outwater E, Matteucci T, Hann H . Early hepatocellular carcinoma that develops within macroregenerative nodules: growth rate depicted at serial MR imaging. Radiology. 1995; 195(3):753-6. DOI: 10.1148/radiology.195.3.7754006. View

Iizuka N, Oka M, Yamada-Okabe H, Hamada K, Nakayama H, Mori N . Molecular signature in three types of hepatocellular carcinoma with different viral origin by oligonucleotide microarray. Int J Oncol. 2004; 24(3):565-74. View

10.

Kim Y, Stolarska M, Othmer H . The role of the microenvironment in tumor growth and invasion. Prog Biophys Mol Biol. 2011; 106(2):353-79. PMC: 3156881. DOI: 10.1016/j.pbiomolbio.2011.06.006. View

11.

Park Y, Choi D, Lim H, Rhim H, Kim Y, Kim S . Growth rate of new hepatocellular carcinoma after percutaneous radiofrequency ablation: evaluation with multiphase CT. AJR Am J Roentgenol. 2008; 191(1):215-20. DOI: 10.2214/AJR.07.3297. View

12.

Sherman M . Hepatocellular carcinoma: screening and staging. Clin Liver Dis. 2011; 15(2):323-34, vii-x. DOI: 10.1016/j.cld.2011.03.003. View

13.

Rodriguez-Brenes I, Komarova N, Wodarz D . Tumor growth dynamics: insights into evolutionary processes. Trends Ecol Evol. 2013; 28(10):597-604. DOI: 10.1016/j.tree.2013.05.020. View

14.

Farazi P, DePinho R . Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006; 6(9):674-87. DOI: 10.1038/nrc1934. View

15.

Ebara M, Hatano R, Fukuda H, Yoshikawa M, Sugiura N, Saisho H . Natural course of small hepatocellular carcinoma with underlying cirrhosis. A study of 30 patients. Hepatogastroenterology. 1998; 45 Suppl 3:1214-20. View

16.

Lee C, Ling Z, Zhao T, Lee K . Distinct expression patterns in hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma. World J Gastroenterol. 2008; 14(39):6072-7. PMC: 2760187. DOI: 10.3748/wjg.14.6072. View

17.

McMahon B, Bulkow L, Harpster A, Snowball M, Lanier A, Sacco F . Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology. 2000; 32(4 Pt 1):842-6. DOI: 10.1053/jhep.2000.17914. View

18.

Kim D, Han K . Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer. 2013; 1(1):2-14. PMC: 3747543. DOI: 10.1159/000339016. View

19.

Daniele B, Bencivenga A, Salomone Megna A, Tinessa V . Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004; 127(5 Suppl 1):S108-12. DOI: 10.1053/j.gastro.2004.09.023. View

20.

Kubota K, Ina H, Okada Y, Irie T . Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography. Dig Dis Sci. 2003; 48(3):581-6. DOI: 10.1023/a:1022505203786. View